Here's a story that deserves way more attention than it's getting. Doctors and researchers at AIIMS Delhi have built an AI breast cancer detection tool that reads mammograms alongside radiologists and flags anything suspicious. And on September 16, the institute formally transferred the technology to Indian healthcare company BPL Technologies, which will now take it through regulatory approval and into hospitals. In a country where breast cancer is often caught late because specialist radiologists are scarce outside metros, this is exactly the kind of AI India needs — quiet, clinical and useful.
01.What the AIIMS breast cancer AI actually does
Think of it as a second pair of eyes that never gets tired. The AI scans a mammogram and alerts the radiologist to any possible signs of cancer, so nothing slips through on a busy day. Dr Krithika Rangarajan, Associate Professor in AIIMS' Department of Diagnostic and Interventional Oncoradiology, described the design intent plainly: "The idea is to act as a second reader and alert the radiologist to any possible cancer, so that they do not miss cancers on mammography."
Crucially, it is not replacing anyone. Patients continue to get their reports from human radiologists — the AI runs alongside as a safety net. It has actually been deployed at AIIMS in trial mode for around a year now, and it is not being used to make clinical decisions on its own.
02.Trained entirely on Indian data — a first
This is the detail I find most exciting. Most medical AI tools in Indian hospitals are imported from the West, trained on Western patient populations, and then patched to work here. The AIIMS model is the first Indian version of a mammography AI model — trained completely on Indian data. That matters because breast density, imaging equipment and presentation patterns differ across populations, and a model that has only ever "seen" Western scans can miss things in Indian ones.
The project took roughly one to one-and-a-half years to develop, with initial funding from the Ministry of Education. Before this week's technology transfer, it was retrospectively tested on around 3,000–4,000 patients at AIIMS.
03.The 99% number, explained honestly
Headlines are quoting "99% accuracy," but the real stat deserves a careful read: the model showed a 99% negative predictive value at the threshold used in the study. In plain terms — when the AI said "no cancer," it was right about 99% of the time in that study setting. That's excellent news for reassurance and for triage, because it means a "clear" result is very likely genuinely clear.
What it doesn't mean is that the AI is 99% right about everything in all conditions — performance depends on the threshold chosen, and wider clinical use still depends on validation and regulatory clearances. Credit to the AIIMS team for framing it as a safety net rather than a miracle machine.
04.From AIIMS lab to your city hospital
The transfer happened at AIIMS on September 16 in the presence of institute director Prof Nikhil Tandon and BPL Technologies chief financial officer Ajay Jindal. BPL will now develop it into a finished product, obtain regulatory clearances and provide technical support for hospital deployment. Dr Rangarajan told The Times of India that it could potentially reach hospitals in around six months, depending on approvals.
The biggest beneficiaries? Hospitals where doctors have limited experience interpreting mammograms, or where breast imaging specialists are simply too few. That describes a huge chunk of India's tier-2 and tier-3 healthcare system, where an extra layer of screening support could be the difference between an early diagnosis and a late one.
05.The bigger picture for Indian healthtech
AI in healthcare is clearly having a moment — we wrote recently about Bill Gates putting $1 billion into AI for healthcare, farming and local languages. What sets the AIIMS project apart is the model: government-funded academic research, built on Indian data, then handed to an Indian company for deployment. If that pipeline repeats across oncology, cardiology and radiology, India could build something most countries can't — public-interest medical AI that doesn't depend on a foreign vendor's pricing page.
It's also a nudge for anyone in tech eyeing healthcare. The tools that will actually work in Indian hospitals are not the flashiest ones — they're the ones scoped narrowly, validated locally, and designed to support doctors rather than replace them. If that inspires you to start building with AI yourself, our GPT-6 Astra — Zero to Hero Guide covers prompting, AI agents and practical business ideas to get you from curious to competent.
Regulation is slowly catching up with medical AI too — India's drug regulator CDSCO has now formed an expert panel to regulate AI in drug discovery.
Key Takeaways
- AIIMS Delhi's AI tool acts as a second reader of mammograms, alerting radiologists to possible cancers
- It is India's first mammography AI model trained completely on Indian patient data
- It showed a 99% negative predictive value when tested on roughly 3,000–4,000 patients
- Technology was transferred to BPL Technologies on September 16 for product development and approvals
- Hospitals could see it in about six months, pending regulatory clearances
Frequently Asked Questions
What is AIIMS Delhi's new breast cancer AI tool?
AIIMS Delhi has developed an AI tool that acts as a “second reader” of mammograms to help catch signs of breast cancer. It is the first mammography AI model trained completely on Indian patient data.
How accurate is AIIMS's mammography AI?
In testing on 3,000–4,000 patients, the model showed a 99% negative predictive value. The technology was transferred to BPL Technologies on September 16, and hospitals could see it in about six months.
What This Means for You
If you or someone in your family has been postponing a mammogram, this is your reminder to book it — AI or no AI, early detection remains the single biggest advantage in beating breast cancer. For students and professionals, this story is proof that the most meaningful AI opportunities in India aren't just in chatbots and image generators — they're in applied, domain-specific problems where a well-scoped AI assistant saves lives. And if you want to be the person building such tools rather than reading about them, start with the fundamentals: our GPT-6 Astra — Zero to Hero Guide is the practical first step.